

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :
C12N 15/12, A61K 37/02
C07K 13/00, C12N 1/21
// (C12N 1/21, C12R 1/19)

A1

(11) International Publication Number:

WO 91/16431

(43) International Publication Date: 31 October 1991 (31.10.91)

(21) International Application Number: PCT/US91/02618
(22) International Filing Date: 19 April 1991 (19.04.91)

(30) Priority data: 24 April 1990 (24.04.90) US
513,729

(60) Parent Application or Grant
(63) Related by Continuation
US
Filed on 513,729 (CIP)
24 April 1990 (24.04.90)

(71) Applicant (for all designated States except US): SCHERING
CORPORATION [US/US]; 2000 Galloping Hill Road,
Kenilworth, NJ 07033 (US).


(72) Inventors; and
(75) Inventors/Applicants (for US only): ZAVODNY, Paul, J.
[US/US]; 279 Central Avenue, Mountainside, NJ 07092
[US/US]; 26 Natalie Drive, West Caldwell, NJ 07006 (US). PETRO, Mary, E.
[US/US]; 17 Cliffside Lane, Green Pond, NJ 07435
(US). LUNDELL, Daniel, J. [US/US]; 21 Sleepy Hollow
Drive, Flemington, NJ 08822 (US). FOSSETTA, James,
D. [US/US]; 14 - 2nd Avenue, Roseland, NJ 08670 (US).

(74) Agents: BLASDALE, John, H., C. et al.; Schering-Plough
Corporation, One Giralda Farms, Madison, NJ
07940-1000 (US).

(81) Designated States: AT (European patent), AU, BB, BE
(European patent), BF (OAPI patent), BG, BJ (OAPI
patent), BR, CA, CF (OAPI patent), CG (OAPI patent),
CH (European patent), CM (OAPI patent), DE (Euro-
pean patent), DK (European patent), ES (European pa-
tent), FI, FR (European patent), GA (OAPI patent), GB
(European patent), GR (European patent), HU, IT (Eu-
ropean patent), JP, KP, KR, LK, LU (European patent),
MC, MG, ML (OAPI patent), MR (OAPI patent), MW,
NL (European patent), NO, RO, SD, SE (European pa-
tent), SN (OAPI patent), SU, TD (OAPI patent), TG
(OAPI patent), US.

Published
With international search report.
Before the expiration of the time limit for amending the
claims and to be republished in the event of the receipt of
amendments.

(54) Title: SOLUBLE, TRUNCATED GAMMA-INTERFERON RECEPTORS



(57) Abstract

Soluble, truncated γ -interferon receptors, especially the soluble, extra-cellular domain of the human receptor, are provided, together with DNA sequences encoding them and transformed cell-lines producing them. Methods are also provided for using such receptors to inhibit the binding of γ -interferon to its cellular receptor.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

SOLUBLE, TRUNCATED GAMMA-INTERFERON RECEPTORSTECHNICAL FIELD

This invention relates to soluble, truncated γ -interferon receptors, and in particular to soluble,
5 extra-cellular portions of the γ -interferon receptor.

BACKGROUND OF THE INVENTION

γ -Interferon, sometimes referred to herein as IFN- γ , is a cytokine produced by activated helper T cells; it
10 has direct effects on several cell types such as B cells, macrophages and T cells. It has multiple effects (Trinchieri et al., Immunology Today, 6:131-136 (1985); one of its most distinguishing activities is that it induces expression of major histocompatibility complex (MHC) class
15 I and class II genes (Kelley et al., J. Immunol., 132:240-245 (1984); Collins et al., Proc. Natl. Acad. Sci. USA, 81:4917-4921 (1984); Cooper et al., J. Immunol., 141:1958-1962 (1988); and Amaldi et al., J. Immunol., 142:999-1004 (1989)). The expression of MHC class II
20 genes is a hallmark of antigen-presenting cells. Expression of class II antigens is seen in macrophages and mature B and T cells; and γ -interferon is known to upregulate this expression. In addition, γ -interferon is known to induce the expression of genes encoding class II
25 antigens in cells that are not primary antigen-presenting

-2-

cells, such as epithelial cells, fibroblasts, astrocytes, endothelial cells, and smooth muscle cells. Whether these types of cells do in fact present antigens is uncertain, but the induction of class II antigens in these cell types has been shown to correlate with the development of autoimmune disease (Massa et al., Proc. Natl. Acad. Sci. USA, 84:4219-4213 (1987)). Since γ -interferon is the primary stimulator of class II antigens, it may play an important part in expression of the disease state. Therefore, an inhibitor of γ -interferon or its effects, for example one that acts at the receptor interface level, would have great potential value and utility in the treatment of auto-immune disease.

Attempts have been made to inhibit the effects of γ -interferon in mice by administering monoclonal antibodies against it (Grau et al., Proc. Natl. Acad. Sci. USA, 86:5572-5574 (1989)). However, in applying this treatment to humans, one would have to bear in mind the possibility that the monoclonal antibodies themselves may induce a neutralizing immune response that could reduce the effectiveness of this treatment.

Recombinant clones expressing γ -interferon receptors are known (see, for example, "Molecular Cloning and Expression of the Human Interferon- γ Receptor", Aguet, G., et al., Cell, 55:273-280 (1988)); but these provide the whole receptor, including the cytoplasmic (intracellular) domain and the trans-membrane domain. The cytoplasmic domain may be responsible for signal transduction in the cell, and is therefore superfluous when one is seeking an IFN- γ antagonist to seek out and selectively bind to IFN- γ in the blood stream or other body fluids (e.g. synovial fluid). Moreover, the cytoplasmic domain is normally concealed within the cell where it is inaccessible to the immune system; the full-length IFN- γ receptor could therefore conceivably act as an antigen by virtue of its

-3-

cytoplasmic domain and be neutralized. If this happened, it could be removed and quickly lose its effect if introduced into such body fluids. There is thus a need for an antagonist to IFN- γ that competes for IFN- γ without the risk of inducing the side-effects associated with it.

5 The encoding DNA and predicted amino acid sequence of the IFN- γ receptor have been disclosed by Aguet et al. (supra), who have postulated that the leader sequence extends from amino acid (residue) 1 through amino acid 14, and that the transmembrane sequence extends from amino acid 246 through amino acid 266 (this is their numbering). The predicted extracellular portion of the IFN- γ receptor is therefore postulated to extend from amino acid 15 through amino acid 245; its postulated structure, including the leader sequence consisting of amino acid residues 1-14, and encoding DNA sequence are shown in SEQ ID NO 1, where the leader sequence bears the numbering -14 to -1, and the predicted extracellular portion bears the numbering 1 through 231.

20 In the following discussion, all the numbering will be given in accordance with that in SEQ ID NO 1, even though it may then vary from that in the publications referred to herein.

25 It is not certain how much of this sequence is necessary for an effective IFN- γ receptor that can specifically bind IFN- γ . However, it is known (Stueber et al., Abstract A3-15, J. Interferon Res., Vol. 9 Suppl. 2 (Oct. 1989)) that amino acid residues 1-198 do not provide an effective receptor whereas amino acid residues 12-231 (including sequences starting earlier than position 12) do provide an effective receptor as produced in *E. coli* according to that abstract, i.e., with six histidine residues at the N- or C-terminus. These histidine residues could conceivably change fundamental properties of the receptor, such as its immunogenicity,

35

-4-

and are therefore highly undesirable when the soluble receptor is intended for use as a pharmaceutical. Our own work indicates that amino acid residues 6-221 do provide an effective receptor, but that other sequences
5 could also be effective.

SUMMARY OF THE INVENTION

The invention therefore provides a soluble receptor for γ -interferon, which consists of the glycosylated or unglycosylated extra-cellular moiety of the natural human
10 γ -interferon receptor substantially free from other proteins, and its functionally equivalent variations. The functionally equivalent variations include not only naturally-occurring allelic forms, but also variations produced by substitution, deletion or addition of one or
15 more (e.g. up to three) amino acid residues but retaining substantially the same binding activity. This soluble IFN- γ receptor preferably has the formula given in SEQ ID NO 2, wherein:

Y is a subsequence of one or more amino acid
20 residues starting from the carboxyl terminus (Pro) of the sequence given in SEQ ID NO 3;

Z is a subsequence of one or more amino acid residues starting from the amino terminus (Ile) of the sequence given in SEQ ID NO 4;

25 and m, n and p are independently 0 or 1.

This soluble receptor is thus the extracellular portion of the IFN- γ receptor, and it competes in a receptor-binding assay for IFN- γ and is an antagonist of the binding of IFN- γ to its cellular receptors; i.e., it
30 competes with the IFN- γ receptors for IFN- γ . Furthermore, it can be used in a binding assay to measure IFN- γ : the

-5-

procedure of Example 4D below can be adapted to a solid-phase format for a high through-put screen for IFN- γ antagonists.

5 The Ser and Arg residues at positions 1 and 2 are encoded by a potential ribosome binding site AGCAGG (usually AGGAGG; cf. Shine and Dalgarno, Proc. Natl. Acad. Sci. USA 71:1342) (1974) (see SEQ ID NO 1), and there is an initiation codon 7-9 base pairs downstream. To eliminate the possibility of a false start in most
10 prokaryotes, e.g. bacteria such as *E. coli*, we prefer to start at the Gly residue in position 6 or at a later position up to position 12. In this way there may be provided an effective soluble IFN- γ receptor comprising amino acid residues 12-221, or in particular longer
15 sequences, for example from amino acid residue 1 and/or up to amino acid residue 231.

A full-length cDNA clone encoding the γ -interferon receptor (see, for example, Aguet et al., Cell, 55:273-280 (1988) (cited above)) was directly isolated by means of
20 the polymerase chain reaction (Friedman et al., Nucl. Acids Res. 16:8718 (1988)) from a λ gt11 placental cDNA library. The portion of the cDNA encoding the soluble portion of the IFN- γ receptor was isolated therefrom and incorporated into a plasmid that expresses it.

25 In one preferred embodiment of the invention, the soluble IFN- γ receptor is as defined above, wherein n is 1, and the subsequence in Y represents the sequence given in SEQ ID NO 5.

In another particularly preferred embodiment of the
30 invention, the soluble IFN- γ receptor is as defined above, wherein m , n and p are all 1, and the sequences represented by Y and Z are completely present; i.e., the soluble IFN- γ receptor has the sequence of amino acid residues 1-231.

-6-

In yet another particularly preferred embodiment of the invention, the soluble IFN- γ receptor is as defined above, wherein m and n are 1 and p is 0, and the sequence represented by Y is completely present; i.e., the soluble IFN- γ receptor has the sequence of amino acid residues 1-221.

In still another particularly preferred embodiment of the invention, the soluble IFN- γ receptor is as defined above, wherein m is 0, n is 1 and p is 0, and the sequence represented by Y is present from (6)Gly; i.e., the soluble IFN- γ receptor has the sequence of amino acid residues 6-221.

In a further particularly preferred embodiment of the invention, the soluble IFN- γ receptor is as defined above, wherein m is 0 and n and p are both 1, the sequence represented by Y is present from (6)Gly, and the sequence represented by Z is completely present; i.e., the soluble IFN- γ receptor has the sequence of amino acid residues 6-231.

In still further particularly preferred embodiments of the invention, the soluble IFN- γ receptor is as defined in the two preceding paragraphs except that m is 1, so that the sequence additionally includes an initial serine residue.

BRIEF DESCRIPTION OF THE FIGURES:

Figure 1 shows the plasmid pDSRS into which the DNA sequence encoding the soluble IFN- γ receptor was inserted.

Figure 2 shows schematically how an *E. coli* expression plasmid for the soluble IFN- γ receptor was constructed.

Figure 3 depicts the competition of the soluble IFN- γ receptor protein produced in *E. coli* with IFN- γ binding on U937 cells; the binding assays were carried out as described in Example 4D.

-7-

DESCRIPTION OF THE INVENTION

All references cited herein are incorporated in their entirety by reference.

Expression vectors encoding and capable of producing
5 the extracellular domain of the IFN- γ receptor cDNA in prokaryotes were used for obtaining prokaryotic clones that produced the soluble (extracellular) portion of the IFN- γ receptor. Prokaryotic cells that can be used
10 include bacteria, especially *E. coli*; many strains of *E. coli* can be used in practicing the present invention. However, the preferred *E. coli* strain is a leaky mutant that allows the soluble IFN- γ receptor to escape from the periplasmic space into the culture medium, whence it can be readily isolated without the complications caused by
15 the presence of most other *E. coli* proteins. The production of such bacteria and their use in the manufacture of recombinant heterologous proteins is disclosed in copending application no. 07/429,588, filed October 31, 1989, which is hereby incorporated by reference.

20 Several different *E. coli* promoters, such as Trp, lac, lpp, λ pL, etc., can be used in the practice of the invention. These promoters direct the expression of heterologous proteins in the cytoplasm. For effective secretion into the periplasmic space, a signal peptide
25 sequence such as one derived from *E. coli* OmpA, *E. coli* alkaline phosphatase, *E. coli* lipoprotein, etc., may be used. The expression plasmid for prokaryotic expression in *E. coli* contains a strong promoter, especially a tandem double promoter such as lpp-lac, followed by a DNA
30 sequence encoding a signal sequence that can transport the heterologous protein into the periplasmic space. This last DNA sequence is preferably the signal sequence derived from an *E. coli* outer-membrane protein, OmpA. The

-8-

signal sequence is followed by the coding sequence of the IFN- γ receptor cDNA.

The construction scheme (shown in Figure 2) used in making this plasmid introduced one additional residue, viz serine, at the start of the mature coding sequence. A translation STOP codon was introduced at the end of the sequence encoding the predicted soluble IFN- γ receptor. A plasmid containing these attributes, when used to transform a mutant *E. coli* strain (e.g., the strain available from the ATCC under Accession No. 53956), produces a fusion protein that is composed of the OmpA signal sequence followed by the sequence of the soluble IFN- γ receptor. The fusion protein is further processed in the periplasm to yield the mature soluble IFN- γ receptor, which leaks into the culture medium.

Eukaryotic cell-lines that can be used include mammalian cell-lines, e.g. COS7, NS-1 and CHO cells, and yeast cells; additionally, insect expression systems, e.g. *Bombyx mori* or *Spodoptera frugiperda*, can be used.

To demonstrate this invention, U937 cells were used as a convenient source of γ -interferon receptors; however, the soluble receptors described herein will of course inhibit the binding of IFN- γ to any cells that bear those receptors. Such cells include, for example, B cells, T cells, eosinophiles, smooth muscle cells, promyelocytes, macrophages, erythroid cells, monocytes, granulocytes, etc.

PURIFICATION

Example 3 below describes the purification of the soluble IFN- γ receptor from *E. coli*, but its procedure can be adapted to the purification of the receptor from other sources such as eukaryotic cells, especially mammalian cells and yeast cells.

MATERIALS AND METHODS

1. REAGENTS

Restriction enzymes were purchased from New England Biolabs., Beverly, MA. *Thermus aquaticus* DNA polymerase and 10X buffer were purchased from Stratagene, LaJolla, CA. Double-stranded plasmid DNA sequencing was done using Sequenase Version 2.0 from United States Biochemical, Cleveland, OH. A λ gt11 human placental cDNA library was purchased from Clontech, Palo Alto, CA.

10 2. SYNTHETIC OLIGONUCLEOTIDES

The following synthetic oligonucleotides were synthesized by standard methods with an Applied Biosystems DNA Synthesizer Model 380A:

	AB697:	See SEQ ID NO 6;
	AB758:	See SEQ ID NO 7;
15	AB759:	See SEQ ID NO 8;
	AB812:	See SEQ ID NO 9;
	AB813:	See SEQ ID NO 10;
	AB870JF:	See SEQ ID NO 11;
20	AB871JF:	See SEQ ID NO 12.

3. The polymerase chain reaction (PCR) was carried out as previously described (Friedmann et al., Nucleic Acids Res. (1988), 16:8718).

4. Human IFN- γ can be purified according to the procedure of Example 4A or be obtained commercially, and antibodies thereto can also be obtained commercially. For example, Genzyme Corp. (Boston, MA) supplies recombinant human IFN- γ (99% pure) under the code HG-IFN, and also rabbit polyclonal anti-human IFN- γ under the code IP-500 for Western blotting.

-10-

EXAMPLES**EXAMPLE 1. ISOLATION AND TRANSIENT EXPRESSION OF THE
FULL-LENGTH IFN- γ RECEPTOR CLONE**

The oligonucleotides AB758 and 759, given in SEQ ID
5 NOS 7 and 8, which are identical to the 5'- and
3'-untranslated regions of the IFN- γ receptor cDNA
sequence, were used in a PCR with placental cDNA library
phage lysate essentially as previously described (Friedman
et al., Nucl. Acids Res. (1988), 16:8718). The PCR was
10 run with a Techne programmable Dri-Block (GRI, Essex, UK),
under the following conditions: denaturation at 95°C for
2 minutes, primer annealing at 50°C for 2 minutes, and
chain extension at 72°C for 2 minutes, all for 30 cycles,
with a final cycle elongation at 72°C for 9 minutes. The
15 PCR products were electrophoresed in a 1% agarose gel, and
a main band of approximately 1.5 kb corresponding to the
full-length IFN- γ receptor coding region was visualized by
staining with ethidium bromide and isolated by electro-
elution. The authenticity of the fragment was confirmed
20 with a second PCR using the oligomer AB758, given in SEQ
ID NO 7, as a 5'-primer and AB697, given in SEQ ID NO 6,
as an internal primer corresponding to sequences in the
intracellular region of the IFN- γ receptor, to produce a
fragment of approximately 1.2 kb.

25 Restriction sites for PstI (5') and SalI (3') were
introduced onto the 1.5 kb full-length IFN- γ receptor
fragment with oligomers AB812 and AB813, given in SEQ ID
NOS 9 and 10, in a PCR as described above. The resulting
fragment was isolated, digested with PstI and SalI and
30 ligated into PstI/SalI-digested pDSRS plasmid (ATCC
Accession No. 68232) (Fig. 1), for expression in COS7
cells. The resulting ligation mixture was used to
transform competent *E. coli* 294 (readily available from

-11-

E. coli Genetics Stock Center, Dept. of Biology, Yale University, P. O. Box 6666, New Haven, CT 06511-7444).

Plasmid DNA isolated by the alkaline lysis method (Birnboim and Doly, "A rapid alkaline extraction procedure for screening recombinant plasmid DNA", Nucl. Acids Res., 7:1513 (1978)) from fourteen of the resulting clones was analysed and checked by restriction analysis and PCR. Seven clones contained the 1.5 kb IFN- γ receptor fragment. DNA from six of these seven clones was purified by cesium chloride/ethidium bromide gradient centrifugation (Maniatis et al.: "Molecular Cloning: A Laboratory Manual", Cold Spring Harbor Laboratory, Cold Spring Harbor, NY) and was transfected transiently into COS7 cells (5 μ g DNA/100mm dish) by the DEAE-dextran method essentially as described (McCutchan and Pagano, "Enhancement of the infectivity of Simian Virus 40 Deoxyribonucleic Acid with Diethylamino-ethyl-Dextran", J. Natl. Cancer Inst., 41:351-356 (1968)). After growth at 37°C for 60-72 hours, the cells were harvested by mild trypsinization and resuspended to 1×10^7 cells/ml in RPMI medium containing 0.02% sodium azide, and kept at 4°C. They were then checked for expression of the IFN- γ receptor by the specific binding of 125 I-labeled IFN- γ , using techniques described in Example 4 below.

Three clones showed a marked increase in specific binding of 125 I-labeled γ -interferon (see Table I below). Plasmid DNA from all three clones was sequenced by the dideoxy chain-termination method (Sanger et al., "DNA Sequencing with Chain-terminating Inhibitors", Proc. Natl. Acad. Sci. U.S.A., 74, 5463-6567 (1977)); the sequence of the extracellular domain was identical to the published sequence (Aguet et al., *supra*).

-12-

EXAMPLE 2. CONSTRUCTION OF pJFR105-6 FOR EXPRESSION OF
GENE ENCODING SOLUBLE IFN- γ RECEPTOR IN E. COLI

Using a DNA fragment isolated from a cDNA library and coding for the γ -interferon receptor, primers were made to introduce two sites for cloning the soluble domain into a prokaryotic expression plasmid. Primer AB870JF, given in SEQ ID NO 12, was made to introduce a HindIII restriction site close to the amino terminus of the DNA (which would be the Gly in position 6); and primer AB871JF, given in SEQ ID NO 13, was made to introduce a BamHI restriction site and a STOP codon, which would serve to isolate and define only the soluble domain of the molecule. (These primers isolate and define the soluble domain of the IFN- γ receptor minus its own leader sequence; i.e., the polypeptide sequence between the leader sequence and the transmembrane region.) Using PCR technology, the DNA fragment (encoding the full-length receptor) and primers were combined in a reaction mixture as follows: 100 pmoles primers, 25 ng DNA, 10 mM dNTPs, 10 μ l TAQ polymerase buffer, and 2 units TAQ polymerase. The system was set at 30 cycles for annealing, denaturation and synthesis, in a total reaction volume of 100 μ l. After the PCR, the DNA was separated on a 1% agarose gel, and the 800 bp fragment encoding the γ -interferon receptor was visualized by staining with ethidium bromide and isolated from the agarose.

Plasmid p830-1 (pINIII, OmpA leader) (D. Lundell et al., "Cytoplasmic and Periplasmic Expression of a Highly Basic Protein, Human Interleukin 4, in E. coli", J. Indust. Microbiol., vol. 4 (1989), and available on request from R. Kastelein at DNAX Research Institute of Molecular and Cellular Biology, Inc., 901 California Avenue, Palo Alto, CA 94304-1104) contains HindIII and BamHI restriction sites, which were used to clone the

-13-

IFN- γ receptor fragment in frame downstream of the OmpA leader as follows: 20 μ g of plasmid DNA was digested with 50 units of HindIII restriction nuclease and then with 40 units of BamHI restriction nuclease. After digestion, the mixture of restriction fragments was run out on a 0.65% agarose gel; a 7.5 kb fragment representing the plasmid backbone was isolated. Any other appropriate plasmid encoding a suitable secretory signal could have been used instead.

10 The 7.5 kb fragment (0.1 μ g) representing the plasmid backbone and 1 μ g of the 800 kb fragment encoding the γ -interferon receptor were ligated in a mixture containing ATP, T4 DNA ligase (100 units), and dithiothreitol at 16°C and in a volume of 40 μ l for 14 hours. Half of the product was then used to transform CaCl₂-prepared *E. coli* (K12) 294 (readily available from *E. coli* Genetics Stock Center, Dept. of Biology, Yale University, P. O. Box 6666, New Haven, CT 06511-7444). The mixture from the transformation was plated onto ampicillin plates and incubated at 30°C for 16-24 hours. Several colonies were then picked and fermented, and DNA was isolated and analysed by digestion with the enzymes mentioned above (HindIII, BamHI), and the clone pJFR105-6 was selected.

25 The pJFR105-6 clone has the fragment inserted downstream of OmpA and under the control of the lpp/lac promoter. The plasmid is derived from pBR322 and carries the LAC-I gene so that expression is inducible with isopropyl-thio- β -galactoside (IPTG).

30 EXAMPLE 3. PURIFICATION OF SOLUBLE HUMAN γ -INTERFERON RECEPTOR FROM *E. COLI*

The extracellular domain of the human IFN- γ receptor was purified from *E. coli* harboring plasmid pJFR105-6. Cells were grown at 30°C in M9 - casamino acids medium

-14-

[1 x M9 minimal salts (Gibco BRL No. M29800B), 3% (w/v) casamino acids, 2 g/l glucose, 0.1 g/l thiamine, and 0.2 g/l magnesium sulfate] to $A_{660} = 1.0$. IPTG was added to 0.5 mM, and fermentation was continued at 30°C overnight (final culture $A_{660} = 3.5$). Conditioned media from a 12-liter culture were collected and then clarified by centrifugation. The clarified supernatant was adjusted to 5% (w/v) trichloroacetic acid (TCA), and protein was allowed to precipitate at 4°C for 60 minutes. The insoluble fraction was collected by centrifugation at 10,000 x g, and resuspended to 120 ml in 200 mM Tris (pH 8) for resolubilization. After incubation at 4°C for 60 minutes, the residue from the resolubilized fraction was collected by centrifugation. The supernatant was adjusted to 4 M urea, 20 mM Tris (pH 8), incubated at 4°C for 30 minutes and then applied to a DEAE Sephadex® Fast Flow column (Pharmacia No. 17-0709-01), equilibrated with a buffer of 20 mM Tris (pH 8), 4 M urea. The column was then eluted with a linear 0 - 0.3 M sodium chloride gradient in the same Tris/urea buffer. The soluble extracellular domain of the human IFN- γ receptor eluted at approximately 0.18 M NaCl. The soluble receptor pool was dialysed against 20 mM Tris (pH 8), and applied to a 5 ml IFN- γ -Affigel 10 column, equilibrated with 20 mM Tris. [Human IFN- γ was covalently coupled to Affigel 10 (Biorad Catalog No. 153-6046), according to procedures recommended by the manufacturer. This affinity resin contained 4 mg IFN- γ /ml support resin.] The column was washed with 10 ml 0.2 M NaCl in 200 mM Tris (pH 8), and then with 10 ml 0.5 M NaCl in 200 mM Tris (pH 8). The soluble receptor was then eluted with 200 mM sodium carbonate buffer, pH 10.3, 0.6 M NaCl. The fractions were neutralized and pooled, and then dialysed against 20 mM sodium phosphate, pH 7.5.

This procedure yielded from 0.7 to 1 mg of soluble IFN- γ receptor per 12-liter fermentation. However, about

-15-

50% of the soluble IFN- γ receptor was present in the TCA-insoluble fraction. This material could be denatured and refolded to yield further active protein.

EXAMPLE 4. ASSAY FOR SOLUBLE γ -INTERFERON RECEPTORS

5 A. Purification of Human γ -Interferon

E. coli 294 harboring plasmid pGIF4-137 (a pBR322-based expression vector having the bacterial lipoprotein (lpp) promoter and encoding a human γ -interferon gene (amino acids 4-137 of the mature protein)) was grown
10 in modified GC medium (20 g/l glycerol, 30 g/l casamino acids (Difco), 20 g/l yeast extract (Difco), 5 g/l KH_2PO_4 , and 1 g/l $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$) at 37°C. At $A_{660} = 7-10$, cells were harvested and lysed by sonic disruption. A cell-free insoluble fraction was then isolated by centrifugation,
15 resuspended in 20 mM Tris (pH 8), 6 M guanidine hydrochloride and 5 mM dithiothreitol, and resolubilized by heating at 56°C for 30 min.

This resolubilized fraction was then loaded onto a 3 x 90 cm Sephracyl 200-SF[®] column (Pharmacia AB), equilibrated in 20 mM Tris (pH 8), 6 mM guanidine hydrochloride
20 at room temperature. After fractionation the fractions containing the γ -interferon (e.g., as detected by Western blot analysis) were pooled, diluted 120-fold in 10 mM NH_4OAc (pH 7), and mixed at 4°C overnight. SP-Sephadex[®]
25 resin (Sigma Chemical Co.) (10 ml as a 1:1 slurry in 20 mM Tris, pH 8) was added to this sample and it was mixed at 4°C for 60 minutes. The resin was filtered off and washed with 10 mM NH_4OAc (pH 7), and purified γ -interferon was eluted with 1 mM NaCl. The purity of this γ -interferon
30 fraction was greater than 95%, as shown by SDS polyacrylamide gel electrophoresis.

-16-

B. Labeling of Human γ -Interferon

^{125}I -labeled human γ -interferon was prepared using Bolton Hunter reagent (New England Nuclear) according to procedures described by the supplier (the labeling
5 reaction contained 70 $\mu\text{g/ml}$ γ -interferon in 20 mM sodium phosphate at pH 8). The final reaction mixture was desalted by dialysis and applied to a 1 x 24 cm Sephadex G75[®] column equilibrated in PBS and 0.2% gelatin to separate polymerized γ -interferon from dimer protein. The
10 γ -interferon pool, labeled to 50 Ci/mM, was stored at 4°C until use.

C. Sample Preparation Using *E. coli*

E. coli 732I (ATCC Accession No. 53956), transformed with the plasmid pJFR105-6, was grown in nutrient medium
15 at 37°C to $A_{660} = 1$. The culture was then induced with 0.1 mM IPTG, and growth was continued at 37°C for 3 hours. Supernatants from induced cultures were checked for expression of the soluble IFN- γ receptor using the binding assay described below.

20 D. Binding Assay

U-937 cells (ATCC Catalog No. CRL 1593) were inoculated from 5% dimethyl sulfoxide, 95% fetal bovine serum frozen stocks into prewarmed RPMI 1640 medium (Hazelton Biologics, Inc.) and then grown and passaged at
25 37°C to cell densities not exceeding 1×10^6 cells/ml. The cells were collected by centrifugation immediately before use, resuspended to 1.25×10^7 cells/ml in RPMI 1640 medium containing 0.02% sodium azide, and stored on ice. All subsequent procedures were carried out at 4°C.

30 Receptor binding assays were performed as follows:

1.25×10^6 U937 cells were used per assay. (Each assay provided a point in Fig. 3.) The ^{125}I -IFN- γ was added at 10,000 cpm equivalents. Supernatant from the

-17-

culture of cells transfected with plasmid T892-5B (expressing the gene for the soluble receptor) was added at increasing volumes ranging from 0 to 100 μ l. Three components were present in the assay: U-937 cells, ¹²⁵I-labelled IFN- γ , and sample containing soluble IFN- γ receptor. Mixtures containing two of these three components were incubated at 4°C for 30 minutes. The third component was then added and incubation was continued at 4°C for 120 minutes. The cells were centrifuged through oil [150 μ l of a 1:1 mixture of dioctyl phthalate (Aldrich Chemical Co.) and dibutyl phthalate (Eastman Kodak Co.)]. The tubes were then quick-frozen, cell pellets were excised from the bottom of each tube, and radioactivity associated with the pellets was determined in a γ -counter.

By way of example, one way of carrying out the foregoing procedure is as follows:

Dilutions of conditioned media suspected of containing soluble receptor were added (in 50 μ l RPMI media) into wells of a 96-well microtiter plate. Labeled γ -interferon (approximately 50,000 cpm in 50 μ l) was added to each well, followed by 100 μ l of the U-937 cell suspension (1.25×10^7 cells/ml). After incubation at 4°C for 2 hours, each reaction mixture was pipetted into a 0.4 ml micro test-tube (Bio-Rad) containing 150 μ l dioctyl phthalate:dibutyl phthalate (1:1). The assay tubes were centrifuged in a swinging bucket rotor and frozen in liquid nitrogen, and the tube tip (containing the frozen cell pellet separated from the reaction liquor by the oil layer) was excised and analysed for radioactivity in a gamma counter. Media fractions able to inhibit the binding of γ -interferon to the U-937 cells were identified as containing soluble IFN- γ receptor.

The results are shown in Table I.

-18-

TABLE I

SCREEN FOR EXPRESSION OF CLONED FULL-LENGTH
 γ -INTERFERON RECEPTOR IN COS7 CELLS

Expt. No.	Plasmid No.	Background Binding (1)	Background Binding (2)	Specific Binding (3)
1	T884-5	1832.8	129.8	1703.0
1'	T884-5	1560.5	77.8	1482.7
2	T886-5	1985.0	150.4	1834.6
2'	T886-5	2404.6	197.6	2207.0
3	T886-6	2525.9	230.9	2295.0
3'	T886-6	2092.8	69.8	2023.0
4	No Insert	110.7	136.8	0
4'	No Insert	159.4	160.0	0
5	No DNA	125.4	184.4	0
5'	No DNA and no chloroquine	158.1	178.3	0

(1) ^{125}I IFN- γ cpm bound at 0.1 $\mu\text{g/ml}$ unlabeled IFN- γ .

(2) ^{125}I IFN- γ cpm bound at 10 $\mu\text{g/ml}$ unlabeled IFN- γ .

(3) Specific binding = (1) - (2).

Figure 3 shows the results of experiments in which the binding of the complete γ -interferon receptor on U937 cells with γ -interferon is compared with the binding of the soluble γ -interferon receptor of this invention with γ -interferon. In this receptor binding assay, the soluble γ -interferon receptor, produced in *E. coli*, competed in a dose-dependent manner in preventing the binding of ^{125}I -labelled γ -interferon to its receptors on U937 cells.

-19-

These data show that the soluble receptor is a competitive inhibitor for the binding of γ -interferon to its cellular receptors. In laboratory test procedures (e.g., screening assays) using this competitive inhibition, the IFN- γ or its soluble receptor can be tagged with a label that is able to generate a signal, e.g., a radiolabel or a chemical label, especially a fluorescent label. Moreover, by virtue of this competitive inhibition, the soluble γ -interferon receptor of the present invention is also likely to find therapeutic use in the treatment of auto-immune diseases such as rheumatoid arthritis, multiple sclerosis, Sjögren's Syndrome and lupus erythematosus.

The soluble IFN- γ receptor of the invention can be administered as a pharmaceutical composition. Such compositions contain a therapeutically effective amount of the soluble receptor of the invention and a pharmaceutical carrier or excipient. A pharmaceutical carrier can be any compatible, non-toxic substance suitable for delivering the soluble IFN- γ receptor of the invention to a patient. Sterile water, alcohol, fats, waxes, and inert solids may for example be included in a carrier, and pharmaceutically acceptable adjuvants (e.g., buffering agents, dispersing agents) may also be incorporated. Generally, compositions useful for parenteral administration of such drugs are well known, e.g. see Remington's Pharmaceutical Sciences, 14th Ed. (Mack Publishing Company, Easton, PA 1980). Alternatively, compositions of the invention may be introduced into a patient's body by an implantable drug delivery system; e.g. see Urquhart et al., Ann. Rev. Pharmacol. Toxicol, vol. 24, pgs. 199-236 (1984).

The soluble IFN- γ receptor of the invention is normally administered parenterally, preferably intravenously. Although the soluble IFN- γ receptor is not

-20-

expected to be immunogenic, it is preferably administered slowly, either by a conventional IV administration set or from a subcutaneous depot.

When administered parenterally, the soluble IFN- γ receptor will normally be formulated with a pharmaceutically acceptable parenteral vehicle in a unit dosage form suitable for injection (e.g., a solution, suspension or emulsion). Such vehicles are inherently non-toxic and non-therapeutic. Examples of such vehicles are normal saline, Ringer's solution, dextrose solution, and Hank's solution. Non-aqueous vehicles such as fixed oils and ethyl oleate may also be used. A preferred vehicle is 5% dextrose/saline. The vehicle may contain minor amounts of additives such as substances that enhance isotonicity and chemical stability, e.g., buffers and preservatives. The soluble IFN- γ receptor is preferably formulated in purified form substantially free of aggregates, degradation products and contaminating proteins, at concentrations of about 5 to 500 $\mu\text{g/ml}$, preferably 20 to 250 $\mu\text{g/ml}$.

Selecting an administration regimen for the soluble IFN- γ receptor depends on several factors, including the serum turnover rate of the soluble IFN- γ receptor, the serum level of IFN- γ associated with the auto-immune disorder, any possible immunogenicity of the soluble IFN- γ receptor, the accessibility of the target IFN- γ , the affinity of IFN- γ to its cellular receptor(s) relative to that of IFN- γ to the soluble IFN- γ receptor, and the like.

Determination of the proper dosage of a compound of the invention for a particular situation is within the skill of the art. Usually, treatment is initiated with dosages that are less than the optimum dose. Thereafter, the dosage is increased by small amounts until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.

-21-

The amount and frequency of administration of the soluble IFN- γ receptor will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated.

According to the administration regimen, the amount of soluble IFN- γ receptor delivered to the patient is preferably maximized consistent with an acceptable level of side effects; and the amount delivered therefore depends in part on the severity of the disease being treated. Preferably, the dose is in the range of about 0.1 to 500 $\mu\text{g/kg}$ per day, more preferably about 1 to 50 $\mu\text{g/kg}$ per day.

A typical recommended dosage regimen is parenteral administration of from 1 $\mu\text{g/day}$ to 5 mg/day, preferably 20 $\mu\text{g/day}$ to .1 mg/day, in two to four divided doses to achieve relief of the auto-immune symptoms.

The descriptions of the foregoing embodiments of the invention have been presented for purpose of illustration and description. They are not intended to be exhaustive or to limit the invention to the precise forms disclosed, and obviously many modifications and variations are possible in the light of the above teachings. The embodiments were chosen and described to explain the principles of the invention and its practical application, so that others skilled in the art would thereby be enabled to use and practise appropriately such embodiments and modifications of the invention as are suited to the particular use contemplated. It is intended that the scope of the invention be defined by the claims appended hereto.

-22-

SEQUENCE LISTING

SEQ ID NO: 1

SEQUENCE TYPE: DNA Sequence with corresponding amino acid sequence

5 SEQUENCE LENGTH: 735 bases; 245 amino acid residues

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA molecule and encoded protein/poly-peptide

10 ORIGINAL SOURCE ORGANISM: Human

PROPERTIES: Soluble receptor for γ -interferon

FEATURES:

from 1 to 42: DNA encoding leader sequence

15 from 43 to 735: DNA encoding human mature soluble gamma-Interferon receptor

ATG GCT CTC CTC TTT CTC CTA CCC CTT GTC ATG CAG GGT GTG 42
 Met Ala Leu Leu Phe Leu Leu Pro Leu Val Met Gln Gly Val
 -10 -5

AGC AGG GCT GAG ATG GGC ACC GCG GAT CTG GGG CCG TCC TCA GTG 87
 20 Ser Arg Ala Glu Met Gly Thr Ala Asp Leu Gly Pro Ser Ser Val
 1 5 10 15

CCT ACA CCA ACT AAT GTT ACA ATT GAA TCC TAT AAC ATG AAC CCT 132
 Pro Thr Pro Thr Asn Val Thr Ile Glu Ser Tyr Asn Met Asn Pro
 20 25 30

25 ATC GTA TAT TGG GAG TAC CAG ATC ATG CCA CAG GTC CCT GTT TTT 177
 Ile Val Tyr Trp Glu Tyr Gln Ile Met Pro Gln Val Pro Val Phe
 35 40 45

ACC GTA GAG GTA AAG AAC TAT GGT GTT AAG AAT TCA GAA TGG ATT 222
 30 Thr Val Glu Val Lys Asn Tyr Gly Val Lys Asn Ser Glu Trp Ile
 50 55 60

GAT GCC TGC ATC AAT ATT TCT CAT CAT TAT TGT AAT ATT TCT GAT 267
 Asp Ala Cys Ile Asn Ile Ser His His Tyr Cys Asn Ile Ser Asp
 65 70 75

-23-

	CAT GTT GGT GAT OCA TCA AAT TCT CTT TGG GTC AGA GTT AAA GCC	312
	His Val Gly Asp Pro Ser Asn Ser Leu Trp Val Arg Val Lys Ala	
	80 85 90	
5	AGG GTT GGA CAA AAA GAA TCT GCC TAT GCA AAG TCA GAA GAA TTT	357
	Arg Val Gly Gln Lys Glu Ser Ala Tyr Ala Lys Ser Glu Glu Phe	
	95 100 105	
	GCT GTA TGC CGA GAT GGA AAA ATT GGA OCA CCT AAA CTG GAT ATC	402
	Ala Val Cys Arg Asp Gly Lys Ile Gly Pro Pro Lys Leu Asp Ile	
	110 115 120	
10	AGA AAG GAG GAG AAG CAA ATC ATG ATT GAC ATA TTT CAC CCT TCA	447
	Arg Lys Glu Glu Lys Gln Ile Met Ile Asp Ile Phe His Pro Ser	
	125 130 135	
	GTT TTT GTA AAT GGA GAC GAG CAG GAA GTC GAT TAT GAT CCC GAA	492
	Val Phe Val Asn Gly Asp Glu Gln Glu Val Asp Tyr Asp Pro Glu	
15	140 145 150	
	ACT ACC TGT TAC ATT AGG GTG TAC AAT GTG TAT GTG AGA ATG AAC	537
	Thr Thr Cys Tyr Ile Arg Val Tyr Asn Val Tyr Val Arg Met Asn	
	155 160 165	
	GGA AGT GAG ATC CAG TAT AAA ATA CTC ACG CAG AAG GAA GAT GAT	582
20	Gly Ser Glu Ile Gln Tyr Lys Ile Leu Thr Gln Lys Glu Asp Asp	
	170 175 180	
	TGT GAC GAG ATT CAG TGC CAG TTA GCG ATT OCA GTA TCC TCA CTG	627
	Cys Asp Glu Ile Gln Cys Gln Leu Ala Ile Pro Val Ser Ser Leu	
	185 190 195	
25	AAT TCT CAG TAC TGT GTT TCA GCA GAA GGA GTC TTA CAT GTG TGG	672
	Asn Ser Gln Tyr Cys Val Ser Ala Glu Gly Val Leu His Val Trp	
	200 205 210	
	GGT GTT ACA ACT GAA AAG TCA AAA GAA GTT TGT ATT ACC ATT TTC	717
	Gly Val Thr Thr Glu Lys Ser Lys Glu Val Cys Ile Thr Ile Phe	
30	215 220 225	
	AAT AGC AGT ATA AAA GGT.	735
	Asn Ser Ser Ile Lys Gly.	
	230	

-24-

SEQ ID NO: 2

SEQUENCE TYPE: Amino acid sequence

SEQUENCE LENGTH: 231 amino acid residues

STRANDEDNESS: single

5 TOPOLOGY: linear

MOLECULE TYPE: protein/polypeptide

ORIGINAL SOURCE ORGANISM: Human

PROPERTIES: Soluble receptor for γ -interferon
(no leader sequence)10 For (Xaa)_n and (Xaa)_p see SEQ ID NOS 3 and 4 respectively(Ser)_m (Xaa)_n Ser Ser Val Pro Thr Pro Thr Asn Val Thr Ile Glu
1 13 15 20Ser Tyr Asn Met Asn Pro Ile Val Tyr Trp Glu Tyr Gln Ile Met
25 30 3515 Pro Gln Val Pro Val Phe Thr Val Glu Val Lys Asn Tyr Gly Val
40 45 50Lys Asn Ser Glu Trp Ile Asp Ala Cys Ile Asn Ile Ser His His
55 60 6520 Tyr Cys Asn Ile Ser Asp His Val Gly Asp Pro Ser Asn Ser Leu
70 75 80Trp Val Arg Val Lys Ala Arg Val Gly Gln Lys Glu Ser Ala Tyr
85 90 95Ala Lys Ser Glu Glu Phe Ala Val Cys Arg Asp Gly Lys Ile Gly
100 105 11025 Pro Pro Lys Leu Asp Ile Arg Lys Glu Glu Lys Gln Ile Met Ile
115 120 125Asp Ile Phe His Pro Ser Val Phe Val Asn Gly Asp Glu Gln Glu
130 135 14030 Val Asp Tyr Asp Pro Glu Thr Thr Cys Tyr Ile Arg Val Tyr Asn
145 150 155Val Tyr Val Arg Met Asn Gly Ser Glu Ile Gln Tyr Lys Ile Leu
160 165 170Thr Gln Lys Glu Asp Asp Cys Asp Glu Ile Gln Cys Gln Leu Ala
175 180 18535 Ile Pro Val Ser Ser Leu Asn Ser Gln Tyr Cys Val Ser Ala Glu
190 195 200Gly Val Leu His Val Trp Gly Val Thr Thr Glu Lys Ser Lys Glu
205 210 21540 Val Cys (Xaa)_p
220

-25-

SEQ ID NO: 3

SEQUENCE TYPE: Amino acid sequence represented by (Xaa)_n
in SEQ. ID. NO. 2

SEQUENCE LENGTH: 11 amino acid residues

5 STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: polypeptide

ORIGINAL SOURCE ORGANISM: Human

10 PROPERTIES: amino acid residues nos. 2 to 12 of soluble
receptor for γ -interferonArg Ala Glu Met Gly Thr Ala Asp Leu Gly Pro.
5 10

SEQ ID NO: 4

15 SEQUENCE TYPE: Amino acid sequence represented by (Xaa)_p
in SEQ. ID. NO. 2

SEQUENCE LENGTH: 10 amino acid residues

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: polypeptide

20 ORIGINAL SOURCE ORGANISM: Human

PROPERTIES: amino acid residues nos. 222 to 231 of soluble
receptor for γ -interferonIle Thr Ile Phe Asn Ser Ser Ile Lys Gly
225 230

-26-

SEQ ID NO: 5

SEQUENCE TYPE: Sub-sequence of amino acid sequence
represented by (Xaa)_n in SEQ. ID. NO. 2

SEQUENCE LENGTH: 7 amino acid residues

5 STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: polypeptide

ORIGINAL SOURCE ORGANISM: Human

10 PROPERTIES: amino acid residues nos. 6 to 12 of soluble
receptor for γ -interferonGly Thr Ala Asp Leu Gly Pro
6 10

SEQ ID NO: 6

SEQUENCE TYPE: Synthetic DNA sequence designated AB697

15 SEQUENCE LENGTH: 23 bases

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA sequence

ORIGINAL SOURCE ORGANISM: None

20 PROPERTIES: internal primer corresponding to the
complement of the sequence in the intracellular region of
the IFN- γ receptor

CAGACTGGTT ACTACTTAAA GGT

23

-27-

SEQ ID NO: 7

SEQUENCE TYPE: Synthetic DNA sequence designated AB758

SEQUENCE LENGTH: 20 bases

STRANDEDNESS: single

5 TOPOLOGY: linear

MOLECULE TYPE: DNA sequence

ORIGINAL SOURCE ORGANISM: None

PROPERTIES: 5'-primer corresponding to sequence in the
5'-untranslated region of the IFN- γ receptor cDNA sequence

10 CAGCGACCGT CGGTAGCAGC

20

SEQ ID NO: 8

SEQUENCE TYPE: Synthetic DNA sequence designated AB759

SEQUENCE LENGTH: 20 bases

STRANDEDNESS: single

15 TOPOLOGY: linear

MOLECULE TYPE: DNA sequence

ORIGINAL SOURCE ORGANISM: None

PROPERTIES: 3'-primer corresponding to the complement of
the sequence in the 3'-untranslated region of the IFN- γ
20 receptor cDNA

CTTCAAAGTT GGTGCAACTT

20

-28-

SEQ ID NO: 9

SEQUENCE TYPE: Synthetic DNA sequence designated AB812

SEQUENCE LENGTH: 27 bases

STRANDEDNESS: single

5 TOPOLOGY: linear

MOLECULE TYPE: DNA sequence

ORIGINAL SOURCE ORGANISM: None

10 PROPERTIES: oligomer to introduce PstI restriction site
into the end of the 1.5 kb full-length IFN- γ receptor
fragment

CTATCTGCAG CGACCGTCGG TAGCAGC

27

SEQ ID NO: 10

SEQUENCE TYPE: Synthetic DNA sequence designated AB813

SEQUENCE LENGTH: 30 bases

15 STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA sequence

ORIGINAL SOURCE ORGANISM: None

20 PROPERTIES: oligomer to introduce SalI restriction site
into the 3'-end of the 1.5 kb full-length IFN- γ receptor
fragment

GTATGTCGAC TTCCAAAGTT GGTGCAACTT

30

-29-

SEQ ID NO: 11

SEQUENCE TYPE: Synthetic DNA sequence designated AB870JF

SEQUENCE LENGTH: 39 bases

STRANDEDNESS: single

5 TOPOLOGY: linear

MOLECULE TYPE: DNA sequence

ORIGINAL SOURCE ORGANISM: None

10 PROPERTIES: 5'-primer to introduce a HindIII restriction
site close to the codon for glycine (in position no. 6) at
the amino terminus of the DNA encoding the soluble IFN- γ
receptor

GCGCAAGCTT CTGGCACCGC GGATCTGGGG CCGTCCTCA 39

SEQ ID NO: 12

SEQUENCE TYPE: Synthetic DNA sequence designated AB871JF

15 SEQUENCE LENGTH: 39 bases

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA sequence

ORIGINAL SOURCE ORGANISM: None

20 PROPERTIES: 3'-primer to introduce a BamHI restriction
site and a STOP codon at the extra-cellular/transmembrane
junction of the IFN- γ receptor (i.e., the STOP codon after
glycine at position 231)

GGCGGATCCT TAACCTTTTA TACTGCTATT GAAAATGAA 39

-30-

CLAIMS:

1. A soluble receptor for γ -interferon (IFN- γ), which consists of the glycosylated or unglycosylated extra-cellular moiety of the natural human IFN- γ transmembrane
5 cellular receptor substantially free from other proteins, and the functionally equivalent variations thereof.

2. The soluble receptor of claim 1 which has the formula given in SEQ ID NO 2;

wherein:

- 10 Y is a subsequence of one or more amino-acids starting from the carboxyl terminus of the sequence given in SEQ ID NO 3;

- Z is a subsequence of one or more amino-acids starting from the amino terminus of the sequence given in
15 SEQ ID NO 4;

and m, n and p are independently 0 or 1.

3. The soluble receptor of claim 2, wherein m and n are both 1, and the subsequence in Y is given in SEQ ID NO 5.

4. The soluble receptor of claim 2 wherein:

- 20 m, n and p are all 1, and the sequences represented by Y and Z are completely present; i.e., the soluble IFN- γ receptor has the sequence of amino acids 1-231; or

- m is 1, and n is 1 and p is 0, and the sequence represented by Y is completely present; i.e., the
25 soluble IFN- γ receptor has the sequence of amino acids 1-221; or

-31-

m is 0, n is 1 and p is 0, and the sequence represented by Y begins with ⁽⁶⁾Gly; i.e., the soluble IFN- γ receptor has the sequence of amino acids 6-221; or

5 m is 0 and n and p are both 1, the sequence represented by Y begins with ⁽⁶⁾Gly, and the sequence represented by Z is completely present; i.e., the soluble IFN- γ receptor has the sequence of amino acids 6-231.

5. The soluble receptor of claim 2 wherein m is 1 and the sequence includes an initial serine residue.

10 6. The soluble receptor of claim 2 wherein m is 1, n is 1 and p is 0, and the sequence represented by Y begins with ⁽⁶⁾Gly; i.e., the soluble IFN- γ receptor has the sequence of amino acids Ser+6-221.

7. The non-glycosylated soluble receptor of claim 1.

15 8. The soluble receptor of claim 2 wherein m is 1 and n and p are both 1, the sequence represented by Y begins with ⁽⁶⁾Gly, and the sequence represented by Z is completely present; i.e., the soluble IFN- γ receptor has the sequence of amino acids Ser+6-231.

20 9. A pharmaceutical composition comprising an effective amount of the soluble receptor of claim 1 and a pharmaceutically acceptable carrier or excipient.

10. A pharmaceutical composition comprising an effective amount of the soluble receptor of claim 2 and a
25 pharmaceutically acceptable carrier or excipient.

11. Plasmid pJFR105-6.

12. A method for inhibiting the binding of IFN- γ to cells having receptors for IFN- γ , which comprises the steps of:

-32-

administering an effective amount of the soluble
IFN- γ receptor of claim 1 to a medium containing cells
having receptors for IFN- γ ; and

5 allowing said soluble receptor to compete for the
cell receptors.

13. A method for inhibiting the binding of IFN- γ to
cells having receptors for IFN- γ , which comprises the
steps of:

10 administering an effective amount of the soluble
IFN- γ receptor of claim 2 to a medium containing cells
having receptors for IFN- γ ; and

allowing said soluble receptor to compete for the
cell receptors.

1/3





FIGURE 1

2/3

21 A.A. OMP A SIGNAL
 ATG.....CAA GCT TCT GAA TTC CAA GCT TGG ATC

HinDIII ↓ EcoRI ↓ HinDIII BamHI ↓

PCR REACTION



DIGEST HINDIII/BAMHI
 LIGATE AND TRANSFORM

HinDIII BamHI
 GAMMA SOLUBLE RECEPTOR








FIGURE 2

3/3



O-O: negative control, *E. coli* 7321 media
●-●, Δ-Δ, ▲-▲: three sister clones from pJFR106 transformation

FIGURE 3

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 91/02618

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC Int. Cl. 5 C 12 N 15/12 A 61 K 37/02 C 07 K 13/00 C 12 N 1/21 //(C 12 N 1/21 ; C 12 R 1:19)		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int. Cl. 5	C 12 N C 07 K A 61 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	EP-A-0 240 975 (YEDA RESEARCH AND DEVELOPMENT CO., ISRAEL) 14 October 1987, see the claims ---	1-13
Y	JOURNAL OF INTERFERON, suppl. 1, vol. 8, (New York, US), D. NOVICK et al.: "Molecular cloning and characterization of a fragment of the human IFN-gamma receptor", page S.58, see the abstract ---	1-13
Y	THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 170, no. 4, 1 October 1989, D. NOVICK et al.: "Soluble cytokine receptors are present in normal human urine", pages 1409-1414, see Introduction, Results, Discussion --- -/-	1-13
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents : ¹⁰</p> <p>* "A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>* "E" earlier document but published on or after the international filing date</p> <p>* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>* "O" document referring to an oral disclosure, use, exhibition or other means</p> <p>* "P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>* "A" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
06-08-1991	17 SEP 1991	
International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer MISS T. TAZELAAR	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		Relevant to Claim No.
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	
Y	CELL, vol. 55, 21 October 1988, M. AUGUET et al.: "Molecular cloning and expression of the human Interferon-gamma receptor", pages 273-280, see the whole article (cited in the application) ---	1-13
P,Y	JOURNAL OF CHROMATOGRAPHY, vol. 510, 27 June 1990, D. NOVICK et al.: "Purification of soluble cytokine receptors from normal human urine by ligand-affinity and immunoaffinity chromatography", pages 331-337, see Abstract, Results, Discussion ---	1-13
P,X	EP-A-0 369 413 (YEDA RESEARCH AND DEVELOPMENT CO., ISRAEL) 23 May 1990, see the whole document ---	1-13
P,X	EP-A-0 393 502 (F. HOFFMANN-LA ROCHE AG, CH) 24 October 1990, see the whole document ---	1-13
P,X	EP-A-0 416 652 (YEDA RESEARCH AND DEVELOPMENT CO., ISRAEL) 13 March 1991, see the whole document ---	1-13
A	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, vol. 85, July 1988, J. CALDERON et al.: "Purification and characterization of the human interferon-gamma receptor from placenta", pages 4837-4841, see the whole document ---	1-13
A	IMMUNOLOGY TODAY, vol. 9, no. 12, 1988, J.A. LANGER et al.: "Interferon receptors", pages 393-400 -----	

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

US 9102618

SA 47013

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on 10/09/91
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0240975	14-10-87	AU-A- 7095887	15-10-87
		JP-A- 63017699	25-01-88
		US-A- 4897264	30-01-90
EP-A- 0369413	23-05-90	AU-A- 4469889	31-05-90
		CA-A- 2002833	14-05-90
		JP-A- 2291269	03-12-90
EP-A- 0393502	24-10-90	AU-A- 5309390	08-11-90
		JP-A- 2303490	17-12-90
EP-A- 0416652	13-03-91	AU-A- 6220690	14-03-91

EPO FORM 1067

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82